[O2–17–06]: SAFETY AND TOLERABILITY OF CRENEZUMAB IN MILD‐TO‐MODERATE AD PATIENTS TREATED WITH ESCALATING DOSES FOR UP TO 25 MONTHS. (1st July 2017) - Asnaghi, Veronica; Lin, Helen; Hu, Nan; Smith, Jillian; Cho, William; Ostrowitzki, Susanne